Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26kDa GST plasmid DNA vaccine in mice

Wei, Feng; Liu, Quan; Gao, Shengyan; Shang, Limin; Zhai, Yujia; Men, Jingtao; Jiang, Li; Zhu, Xing‐Quan; Fu, Zhiqiang; Shi, Yiting; Xia, Zhang; Lin, Jiaojiao

doi:10.1016/j.vaccine.2008.05.034

Cited by 33 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to IL-12, IL-18 facilitates Th1 immune responses, and depending on the cytokine constellation, IL-18 may also promote Th2 type responses. As a vaccine adjuvant (15,19) and an immunomodulatory molecule, IL-18 modulates the immune response toward a Th1 type and enhances the immune responses to DNA vaccines (19,33).…”

mentioning

confidence: 99%

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen

Wang

et al. 2014

Viral Immunology

View full text Add to dashboard Cite

In this study, two recombinant plasmids containing the ORF2 gene of porcine circovirus type 2 (PCV2) with or without porcine interleukin-18 (IL-18) were constructed and evaluated for their ability to protect piglets against PCV2 challenge. Transient expression of the plasmids in PK-15 cells could be detected using Western blot. Piglets were given two intramuscular immunizations 3 weeks apart and were challenged with a virulent Wuzhi strain of PCV2 at 42 days after the initial immunization. All animals vaccinated with pBudCE4

show abstract

mentioning

confidence: 99%

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen

Wang

et al. 2014

Viral Immunology

View full text Add to dashboard Cite

show abstract

“…The present study has confirmed that IgG1 and IgG2a were produced at approximately equal levels following mucosal immunization, which indicates a mixed Th1/Th2 cytokine response in our spore-based model of vaccination using SjGST antigen. Immunizations with recombinant Sm28 GST in aluminum hydroxide only induced a strong Th2-associated antibody (IgG1) and cytokine (IL-4) response (Comoy et al 1997), and IL-18 as adjuvant induced the Th1-dominant response of Sj26GST DNA vaccine (Wei et al 2008), while we induced a "balanced" IgG isotype, redolent of a mixed Th1/ Th2 profile which was not achieved with aluminum adjuvant or DNA vaccines. The polyfunctionality of induced Th1 and Th2 responses is considered of equal or greater importance for protection.…”

Section: Discussionmentioning

confidence: 82%

“…According to the immunization studies, recombinant SjGST induced reduction in worm burden and egg production rates of S. japonicum in different animal models (Liu et al 1995a, b;Xu et al 1995;Taylor et al 1998;Wu et al 2004;Wei et al 2008); the results seemed quite promising in spite of its not more than 40% protection. Therefore, promotion of protective effect depends on more efficient delivery systems and more efficient vaccinating way.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein

et al. 2009

Parasitol Res

View full text Add to dashboard Cite

One of the promising approaches in mucosal immunization relies on live recombinant vaccine carriers. In this study, we used a six-extracellular protease-deficient Bacillus subtilis strain WB600 to express Schistosoma japonicum 26 kDa glutathione S-transferase (GST). Western blot, immunofluorescence, and flow cytometry analyses were used to identify SjGST expression on spore surface. SjGST recombinant spores were used for oral vaccination in mice and were shown to generate mucosal and systemic response. Both SjGST-specific secretory IgA in feces and IgG in serum augmented significantly on day 33 after oral administration. It seemed that surface display of recombinant S. japonicum SjGST on B. subtilis WB600 spores showed good immunogenicity, and B. subtilis spores could be used as potential mucosal delivery vehicles to provide more effective vaccination strategies for parasite prevention and control in the future.

show abstract

“…The resulting plasmid was named pVAX-ROP13. The plasmid pVAX/IL-18 was extracted previously in our laboratory (23). The concentrations of pVAX-ROP13 and pVAX/ IL-18 were determined using a spectrophotometer at optical densities at 260 and 280 nm (OD 260 and OD 280 ).…”

Section: Methodsmentioning

confidence: 99%

Protective Efficacy of a Toxoplasma gondii Rhoptry Protein 13 Plasmid DNA Vaccine in Mice

Wang

Yuan

Petersen

et al. 2012

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

f Toxoplasma gondii is an obligate intracellular parasite infecting humans and other warm-blooded animals, resulting in serious public health problems and economic losses worldwide. Rhoptries are involved in T. gondii invasion and host cell interaction and have been implicated as important virulence factors. In the present study, a DNA vaccine expressing rhoptry protein 13 (ROP13) of T. gondii inserted into eukaryotic expression vector pVAX I was constructed, and the immune protection it induced in Kunming mice was evaluated. Kunming mice were immunized intramuscularly with pVAX-ROP13 and/or with interleukin-18 (IL-18). Then, we evaluated the immune response using a lymphoproliferative assay, cytokine and antibody measurements, and the survival times of mice challenged with the virulent T. gondii RH strain (type I) and the cyst-forming PRU strain (type II). The results showed that pVAX-ROP13 alone or with pVAX/IL-18 induced a high level of specific anti-T. gondii antibodies and specific lymphocyte proliferative responses. Coinjection of pVAX/IL-18 significantly increased the production of gamma interferon (IFN-␥), IL-2, IL-4, and IL-10. Further, challenge experiments showed that coimmunization of pVAX-ROP13 with pVAX/IL-18 significantly (P < 0.05) increased survival time (32.3 ؎ 2.7 days) compared with pVAX-ROP13 alone (24.9 ؎ 2.3 days). Immunized mice challenged with T. gondii cysts (strain PRU) had a significant reduction in the number of brain cysts, suggesting that ROP13 could trigger a strong humoral and cellular response against T. gondii cyst infection and that it is a potential vaccine candidate against toxoplasmosis, which provided the foundation for further development of effective vaccines against T. gondii.

show abstract

Enhancement by IL-18 of the protective effect of a Schistosoma japonicum 26kDa GST plasmid DNA vaccine in mice

Cited by 33 publications

References 33 publications

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Immunogenicity of self-adjuvanticity oral vaccine candidate based on use of Bacillus subtilis spore displaying Schistosoma japonicum 26 KDa GST protein

Protective Efficacy of a Toxoplasma gondii Rhoptry Protein 13 Plasmid DNA Vaccine in Mice

Contact Info

Product

Resources

About